CNTX earnings analysis
What we found in CNTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Context Therapeutics Inc. reported a net loss of $8.68 million for Q4 2025, which represents a significant increase of 89.6% compared to a net loss of $4.58 million in Q4 2024. The company experienced no revenue during this quarter, continuing a trend of generating no revenue since its inception. Operating expenses surged to $9.34 million, primarily driven by increased research and development activities for its clinical trials.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Recorded
- The company reported zero revenue for Q4 2025, maintaining a trend established since inception.
- Increased Net Loss
- Net loss increased by 89.6% to $8.68 million from $4.58 million year-over-year.
- Surge in Operating Expenses
- Overall operating expenses rose sharply to $9.34 million, up from $5.53 million in the prior year, mainly due to R&D expenditure.
- Cash Reserves Enough Until Mid-2027
- As of March 31, 2026, cash and cash equivalents stood at $54.5 million, which the management expects to fund operations into mid-2027.
- R&D Spending Spike
- R&D expenses increased by $3.6 million to $7.02 million compared to $3.46 million in the previous year.
- Higher Interest Income
- Interest income for the quarter was $520,139, down from $958,517, reflecting reduced cash balances.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk of Further Dilution
- The company will need to raise additional capital, potentially leading to further dilution for existing shareholders.
- No Revenue Generation Timeline
- The lack of expected revenue generation delays financial stability, with profitability still years away.
- Dependence on Equity Financing
- Future funding requirements may heavily depend on the company’s ability to raise funds through equity offerings, which may not be guaranteed.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.14
What they said about what is next.
Management stated that they do not expect to generate significant revenue from product sales for several years.
The filing reads worse than the one before it.
What came before.
- 10-K · March 23, 2026
- Context Therapeutics is a clinical-stage T‑cell engager (TCE) bispecific antibody company advancing three programs (CTIM-76, CT-95, CT-202) toward and into Phase 1. The 10-K emphasizes clinical milestones (IND clearance…
- 10-Q · August 6, 2025
- Context Therapeutics reported no revenue and a wider net loss of $8,827,510 for the three months ended June 30, 2025 (EPS $(0.09)), versus a net loss of $2,254,506 (EPS $(0.04)) in Q2 2024. R&D spending ramped…
- 10-Q · May 7, 2025
- Context Therapeutics reported no revenue for the quarter and a net loss of $4,577,261 (EPS $(0.05)) for the three months ended March 31, 2025. Cash and cash equivalents were $89,352,227 (down $5,077,597 from $94,429,824…
- 10-K · March 21, 2024
- Context Therapeutics is a preclinical biopharma focused on a CLDN6xCD3 bispecific antibody, CTIM-76, with IND-enabling work ongoing and an IND filing expected by the end of March 2024. The company reports strong…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CNTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever